ShareHope Medicine Co., Ltd. (TPEX:8403)
Taiwan · Delayed Price · Currency is TWD 18.95
0.00 (0.00%)
Sep 8, 2026, 1:10 PM CST
ShareHope Medicine Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,496 | 4,358 | 4,326 | 3,873 | 4,137 | 3,850 | |
Revenue Growth | 2.52% | 0.74% | 11.68% | -6.38% | 7.46% | -6.07% |
Cost of Revenue | 3,779 | 3,649 | 3,611 | 3,147 | 3,153 | 3,016 |
Gross Profit | 717.24 | 709.01 | 714.4 | 726.38 | 983.91 | 833.96 |
Selling, General & Admin | 603.43 | 618.16 | 727.54 | 697.17 | 718 | 664.41 |
Research & Development | 3.11 | 5.62 | 11.82 | 12.3 | 16.4 | - |
Other Operating Expenses | -74.23 | -77.75 | -78.51 | -80.88 | -77.84 | -69.2 |
Operating Expenses | 519.26 | 550.45 | 671.79 | 631.69 | 654.53 | 579.7 |
Operating Income | 197.97 | 158.56 | 42.61 | 94.69 | 329.38 | 254.26 |
Interest Expense | -46.52 | -47.81 | -57.39 | -53.64 | -38.12 | -20.1 |
Interest & Investment Income | 20.94 | 16.47 | 57.61 | 10.26 | 6.06 | 5.1 |
Earnings From Equity Investments | -2.09 | -1.23 | 0.44 | -1.85 | -0.4 | -0.22 |
Currency Exchange Gain (Loss) | 2.28 | -0.56 | 2.81 | 0.9 | 10.95 | -4.17 |
Other Non Operating Income (Expenses) | 13.44 | 16.04 | 24.33 | 24.41 | 70.85 | 15.63 |
EBT Excluding Unusual Items | 186.03 | 141.48 | 70.4 | 74.77 | 378.7 | 250.5 |
Gain (Loss) on Sale of Investments | 2.46 | -3.63 | 9.28 | 8.89 | 2.96 | 38.59 |
Gain (Loss) on Sale of Assets | 3.14 | 4.53 | 135.64 | 23.91 | 9.13 | 3.71 |
Asset Writedown | -1.26 | -1.26 | -41.65 | 0.92 | -51.47 | -25.65 |
Other Unusual Items | 8.41 | 9.02 | 0.24 | 0.5 | 0.6 | 0.48 |
Pretax Income | 198.79 | 150.15 | 173.91 | 108.98 | 339.94 | 267.63 |
Income Tax Expense | 44.2 | 38.25 | 51.51 | 53.72 | 95.83 | 74.2 |
Earnings From Continuing Operations | 154.59 | 111.9 | 122.4 | 55.27 | 244.11 | 193.43 |
Minority Interest in Earnings | 7.58 | 29.83 | 77.7 | 69.29 | 49.84 | 39.24 |
Net Income | 162.17 | 141.73 | 200.1 | 124.56 | 293.95 | 232.66 |
Net Income to Common | 162.17 | 141.73 | 200.1 | 124.56 | 293.95 | 232.66 |
Net Income Growth | -0.73% | -29.17% | 60.65% | -57.63% | 26.34% | -6.08% |
Shares Outstanding (Basic) | 138 | 138 | 138 | 138 | 138 | 138 |
Shares Outstanding (Diluted) | 138 | 138 | 138 | 138 | 139 | 139 |
Shares Change | 0.02% | -0.02% | 0.03% | -0.26% | -0.28% | -1.83% |
EPS (Basic) | 1.18 | 1.03 | 1.45 | 0.90 | 2.14 | 1.69 |
EPS (Diluted) | 1.18 | 1.03 | 1.45 | 0.90 | 2.12 | 1.68 |
EPS Growth | -0.60% | -28.99% | 60.26% | -57.41% | 26.73% | -4.75% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 333.56 | 240.15 | 183.6 | 6.83 | -623.51 | 222.59 |
Free Cash Flow Per Share | 2.41 | 1.74 | 1.33 | 0.05 | -4.50 | 1.60 |
Dividend Per Share | - | - | 0.500 | 0.366 | 0.436 | 0.415 |
Dividend Growth | - | - | 36.50% | -16.01% | 5.01% | 5.01% |
Gross Margin | 15.95% | 16.27% | 16.52% | 18.75% | 23.78% | 21.66% |
Operating Margin | 4.40% | 3.64% | 0.98% | 2.44% | 7.96% | 6.60% |
Profit Margin | 3.61% | 3.25% | 4.63% | 3.22% | 7.11% | 6.04% |
Free Cash Flow Margin | 7.42% | 5.51% | 4.24% | 0.18% | -15.07% | 5.78% |
EBITDA | 385.08 | 355.09 | 268.82 | 276.12 | 499.51 | 435.05 |
EBITDA Margin | 8.57% | 8.15% | 6.21% | 7.13% | 12.07% | 11.30% |
D&A For EBITDA | 187.11 | 196.53 | 226.21 | 181.43 | 170.13 | 180.79 |
EBIT | 197.97 | 158.56 | 42.61 | 94.69 | 329.38 | 254.26 |
EBIT Margin | 4.40% | 3.64% | 0.98% | 2.44% | 7.96% | 6.60% |
Effective Tax Rate | 22.24% | 25.48% | 29.62% | 49.29% | 28.19% | 27.73% |